
AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.
Sales increased 9.1% on a reported basis or 8.4% on an operational basis. The company reported adjusted earnings of $1.86 per share, down 38%, beating the consensus of $1.79.